Metabolic Disease News and Research

RSS

Helping diabetics through the holiday season

November ushers in American Diabetes Month - not only a time to be thankful for bustling basic and clinical research underway on the disease, but also the unofficial start of the holiday season.

20 Nov 2008

NicOx's Naproxcinod shows highly significant reduction in daytime blood pressure versus Naproxen

NicOx S.A. has announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA.

12 Nov 2008

Obesity reality check

Sydney University's Institute of Obesity, Nutrition & Exercise (IONE) will today draw together some of Australia's leading obesity experts to review and measure the effectiveness of our response as a nation to the obesity epidemic.

27 Oct 2008

Discovery offers new understanding of diabetes drug target

Scientists at the University of Leicester have published findings about a new advance in the study of major diabetes drug target.

25 Sep 2008

Healthy individuals may be at risk for heart disease

In the face of a growing obesity epidemic in the United States, researchers at Wake Forest University Baptist Medical Center have new study results that indicate that how much fat a person has is not as important as where that fat is located when assessing risk for cardiovascular events and metabolic disease.

8 Sep 2008

How fat, less important than where that fat is!

The latest research from the U.S. says how fat a person is may be less important than where that fat is.

8 Sep 2008

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Research finds a role for the GABA neurotransmitter in maintaining energy balance

Controlling body weight is a complicated process, as any frustrated dieter might attest. But as scientists continue to investigate the brain's intricate neurocircuitry and its role in maintaining energy balance, they are forming a clearer picture of the myriad events that lead to weight gain and weight loss.

10 Aug 2008

Having a big bum may protect you from diabetes!

Researchers at Harvard Medical School in the U.S. suggest that having a big bum may be a good thing from a health perspective.

7 May 2008

NicOx signs agreement for commercial manufacture of Naproxcinod drug substance

NicOx S.A. (Euronext Paris: COX) has announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API).

20 Mar 2008

Alternative treatment method offers effective way to treat Crohn's disease

An international research study, published in The Lancet, has thrown into question the current method of treating Crohn's disease - opening the door to a safer and more effective treatment option for sufferers of the chronic disease.

22 Feb 2008

Brain may have important influences on glucose metabolism and insulin action

An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press.

13 Nov 2007

Brain appears to play important role in glucose metabolism and insulin action

6 Nov 2007

Inflammation causes insulin resistance not obesity

Researchers at the University of California, San Diego (UCSD) School of Medicine have discovered that inflammation provoked by immune cells called macrophages leads to insulin resistance and Type 2 diabetes.

6 Nov 2007

Your Apo E genotype plays part in likelihood of Alzheimer's and heart disease

We all carry the Apo E gene. It plays a key role in the development of Alzheimer's Disease and heart disease, along with a host of chronic ailments.

6 Nov 2007

New understanding of endoplasmic reticulum

In obese individuals, fat cells are bloated and inflamed because they receive too many nutrients, including lipids.

29 Aug 2007

New Australian centre for obesity, nutrition, exercise and public health

The Institute of Obesity, Nutrition & Exercise will draw together some of Australia's leading researchers, scientists and academics in four key divisions; Obesity, Nutrition, Exercise, and Public Health, Epidemiology and Policy.

27 Jul 2007

Roche and Alnylam form RNAi therapeutics alliance

Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced today that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics.

9 Jul 2007

Once-fatal metabolic disorders treatable

People with a class of rare genetic disorders that often lead to brain damage, coma and death can be successfully treated with drugs, says a researcher at the Stanford University School of Medicine and Lucile Packard Children's Hospital.

1 Jun 2007

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Bristol-Myers Squibb Company and Isis Pharmaceuticals have announced a collaboration to discover, develop and commercialize novel antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for the prevention and treatment of cardiovascular disease.

10 May 2007